FoxWayne Enterprises Acquisition Corp. (FOXW)
| Market Cap | 73.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 1.81M |
| Shares Out | 7.24M |
| EPS (ttm) | 0.25 |
| PE Ratio | 40.60 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,697 |
| Open | 10.12 |
| Previous Close | 10.13 |
| Day's Range | 10.11 - 10.12 |
| 52-Week Range | 9.70 - 10.14 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About FOXW
FoxWayne Enterprises Acquisition Corp. does not have significant business. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire a business in the biotechnology and/or telemedicine sector of the healthcare industry in North America. The company was incorporated in 2020 and is based in New York, New York. [Read more...]
News
Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Co...
DURHAM, N.C. and NEW YORK, March 4, 2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory an...
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxW...
DURHAM, N.C. and NEW YORK, Dec. 7, 2021 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc. ("Aerami" or the "Company"), a biopharmaceutical company focused on developing inhaled therapies to treat sever...
FoxWayne Enterprises Acquisition Corp. Announces Closing of $57,500,000 Initial Public Offering Including Full Exerci...
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- FoxWayne Enterprises Acquisition Corp. ("FoxWayne" or the "Company") announced today that has closed its initial public offering of 5,750,000 units at $10.00 per ...